Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether 18F-Al labeled RGD is safety and effective for cancer diagnosis and therapy response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics

NCT03094897

Breast Neoplasms Prostatic Neoplasms

UNKNOWN EARLY_PHASE1

Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors

NCT06690216

Glioblastoma (GBM) Head and Neck Squamous Cell Carcinoma Non-Small Cell Lung Cancer +1 more

ENROLLING_BY_INVITATION PHASE1/PHASE2

4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

NCT03568799

Lung Cancer Solitary Pulmonary Nodule Cigarette Smoking Behavior

UNKNOWN NA

18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma

NCT04813705

Nasopharyngeal Carcinoma

RECRUITING PHASE2

18F-FSPG PET/CT Imaging in Patients With Cancers

NCT03144622

Pulmonary Cancer Breast Neoplasms Abdominal Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors Carcinoma, Bronchogenic Breast Carcinoma Cancer of Head and Neck Lymphoma, Malignant Soft Tissue Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18F-Al-NOTA-PRGD2 PET/CT

Imaging with 18F-Al-NOTA-PRGD2 PET/CT.

Group Type EXPERIMENTAL

18F-Al-NOTA-PRGD2 PET/CT

Intervention Type DRUG

18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

18F-Al-NOTA-PRGD2 PET/CT

18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

18F-Alfatide II PET/CT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Volunteers or patients with age more than 18 yeas;
2. The patients have been diagnosed with cancer or suspected with cancer;
3. It must fulfill the ethical requirements and subjects have signed an informed consent.

Exclusion Criteria

1. Pregnancy or nursing mothers;
2. Having drugs or alcohol dependence;
3. Hypersensitive to the active or inactive ingredients of the study drug;
4. Having attended other drug clinical trials within three months;
5. Cardiac functional insufficiency;
6. Hepatic and renal function insufficiency;
7. Hypertensive patients with serious complications;
8. Endangering the safety of life.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes